
<http://bio2rdf.org/drugbank_resource:a57533055c136af9a471684ba442d058> a <http://schema.org/Organization> ;
	<http://schema.org/name> "Novartis pharmaceuticals corp" .

<http://bio2rdf.org/drugbank:DB00206> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Reserpine" ;
	<http://schema.org/description> "An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. [PubChem]" ;
	<http://schema.org/drugClass> "Antihypertensive Agents" , "Adrenergic Antagonists" , "Adrenergic Uptake Inhibitors" , "Antipsychotic Agents" ;
	<http://schema.org/url> "https://schemaorg.metadatacenter.org/drugbank/DB00206.html" ;
	<http://schema.org/administrationRoute> "oral" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:0b62ca19764dd580eb381bfe12bdff7f> , <http://bio2rdf.org/drugbank_resource:7f5afbd946cf3a1ea7a02ee0e26abb52> ;
	<http://schema.org/clinicalPharmacology> "Reserpine is an adrenergic blocking agent used to treat mild to moderate hypertension via the disruption of norepinephrine vesicular storage. The antihypertensive actions of Reserpine are a result of its ability to deplete catecholamines from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral resistance." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:3086a4d22dbbca472f1c5ec1161f360e> , <http://bio2rdf.org/drugbank_resource:5df63f00794d15d27dc9dfa9969baa78> ;
	<http://schema.org/dosageForm> "Tablet" ;
	<http://schema.org/foodWarning> "Magnesium, potassium and zinc needs increased." ;
	<http://schema.org/interactingDrug> "DDI between Reserpine and Metyrosine - CNS Depressants may enhance the sedative effect of Metyrosine." , "DDI between Reserpine and Pindolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Maprotiline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Fentanyl - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Vardenafil - May enhance the antihypertensive effect of Antihypertensives." , "DDI between Reserpine and Afatinib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib." , "DDI between Reserpine and prucalopride - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride." , "DDI between Reserpine and Levomilnacipran - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Amitriptyline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Dextroamphetamine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Acebutolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Dronabinol - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Alfuzosin - May enhance the hypotensive effect of Antihypertensives." , "DDI between Reserpine and Silodosin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin." , "DDI between Reserpine and Cyclobenzaprine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Fluvoxamine and Reserpine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Primidone - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Bisoprolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Nortriptyline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Tadalafil - May enhance the antihypertensive effect of Antihypertensives." , "DDI between Reserpine and Hydrocodone - CNS Depressants may enhance the CNS depressant effect of Hydrocodone." , "DDI between Reserpine and Tetrabenazine - Reserpine may enhance the adverse/toxic effect of Tetrabenazine." , "DDI between Reserpine and Sotalol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Phentermine and Reserpine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Pethidine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Quinidine - Reserpine may enhance the adverse/toxic effect of QuiNIDine." , "DDI between Reserpine and Isocarboxazid - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Lorcaserin - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Dextromethorphan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Pramipexole - CNS Depressants may enhance the sedative effect of Pramipexole." , "DDI between Reserpine and Nebivolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Donepezil - Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients." , "DDI between Reserpine and Fluoxetine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Metoclopramide - Metoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents." , "DDI between Reserpine and Escitalopram - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Ergonovine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Risperidone - Hypotensive Agents may enhance the hypotensive effect of RisperiDONE." , "DDI between Reserpine and Perampanel - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Esmolol and Reserpine - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Sertraline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Betaxolol and Reserpine - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Doxylamine - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Topotecan - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan." , "DDI between Reserpine and Zolpidem - CNS Depressants may enhance the CNS depressant effect of Zolpidem." , "DDI between Reserpine and Timolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Venlafaxine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Levobunolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Amifostine - Antihypertensives may enhance the hypotensive effect of Amifostine." , "DDI between Reserpine and Bendroflumethiazide - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Protriptyline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Ergoloid mesylate - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Labetalol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Hexobarbital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Everolimus - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus." , "DDI between Reserpine and Phenelzine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Secobarbital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Lisdexamfetamine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Rotigotine - CNS Depressants may enhance the sedative effect of Rotigotine." , "DDI between Reserpine and Benzphetamine - May diminish the stimulatory effect of Amphetamines." , "DDI between Amphetamine and Reserpine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Dihydroergotamine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Rasagiline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Magnesium Sulfate - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Digoxin - May enhance the adverse/toxic effect of Cardiac Glycosides." , "DDI between Reserpine and Zolmitriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Metipranolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Duloxetine - Hypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine." , "DDI between Reserpine and Almotriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Buspirone - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Propranolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Butabarbital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Methylergometrine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Metoprolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Phendimetrazine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Carteolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Thalidomide - CNS Depressants may enhance the CNS depressant effect of Thalidomide." , "DDI between Reserpine and Paroxetine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Moclobemide - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Bosutinib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib." , "DDI between Reserpine and Butethal - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Milnacipran - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Rituximab and Reserpine - Antihypertensives may enhance the hypotensive effect of RiTUXimab." , "DDI between Reserpine and Suvorexant - CNS Depressants may enhance the CNS depressant effect of Suvorexant." , "DDI between Reserpine and Nadolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Methadone - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Tapentadol - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Promethazine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Iobenguane - May diminish the therapeutic effect of Iobenguane I 123." , "DDI between Reserpine and Galantamine - Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients." , "DDI between Reserpine and Rivaroxaban - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban." , "DDI between Reserpine and Yohimbine - May diminish the antihypertensive effect of Antihypertensives." , "DDI between Reserpine and Citalopram - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Methohexital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Procarbazine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Cathinone - Gastrointestinal Acidifying Agents may decrease the serum concentration of Amphetamines." , "DDI between Reserpine and Buprenorphine - CNS Depressants may enhance the CNS depressant effect of Buprenorphine." , "DDI between Reserpine and Rifaximin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin." , "DDI between Reserpine and Obinutuzumab - Antihypertensives may enhance the hypotensive effect of Obinutuzumab." , "DDI between Reserpine and Clomipramine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Diazoxide - May enhance the hypotensive effect of Antihypertensives." , "DDI between Reserpine and Eletriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Lithium - Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine." , "DDI between Reserpine and Trimipramine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Rizatriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Tedizolid Phosphate - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Rivastigmine - Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients." , "DDI between Reserpine and Imipramine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Ropinirole - CNS Depressants may enhance the sedative effect of ROPINIRole." , "DDI between Reserpine and Sumatriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Naratriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Ergotamine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Nabilone - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Mirtazapine - CNS Depressants may enhance the CNS depressant effect of Mirtazapine." , "DDI between Reserpine and Methotrimeprazine - CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Brentuximab vedotin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased." , "DDI between Reserpine and Tranylcypromine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Linezolid - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Penbutolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Desipramine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Pazopanib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib." , "DDI between Reserpine and Droperidol - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Tramadol and Reserpine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Desvenlafaxine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Nefazodone - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Orphenadrine - CNS Depressants may enhance the CNS depressant effect of Orphenadrine." , "DDI between Reserpine and Atenolol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Amoxapine - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Vilazodone - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Frovatriptan - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Ledipasvir - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir." , "DDI between Reserpine and Dabigatran etexilate - P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate." , "DDI between Reserpine and Cabergoline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Hydroxyzine - May enhance the CNS depressant effect of CNS Depressants." , "DDI between Reserpine and Carvedilol - May enhance the hypotensive effect of Beta-Blockers." , "DDI between Reserpine and Methamphetamine - May diminish the stimulatory effect of Amphetamines." , "DDI between Reserpine and Pentobarbital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Rufinamide - May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced." , "DDI between Reserpine and Colchicine - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased." , "DDI between Reserpine and Selegiline - Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome." , "DDI between Reserpine and Pentoxifylline - May enhance the hypotensive effect of Antihypertensives." , "DDI between Reserpine and Heptabarbital - May enhance the hypotensive effect of Hypotensive Agents." , "DDI between Reserpine and Methylphenidate - May diminish the antihypertensive effect of Antihypertensives." ;
	<http://schema.org/legalStatus> "Approved" ;
	<http://schema.org/manufacturer> <http://bio2rdf.org/drugbank_resource:a57533055c136af9a471684ba442d058> ;
	<http://schema.org/mechanismOfAction> "Reserpine's mechanism of action is through inhibition of the ATP/Mg<sup>2+</sup> pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines." ;
	<http://schema.org/nonProprietaryName> "3,4,5-trimethoxybenzoyl methyl reserpate" , "Serpalan" , "Apoplon" , "Reserpin" , "(3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester" , "Reserpine" , "(âˆ’)-reserpine" , "(-)-Reserpine" ;
	<http://schema.org/proprietaryName> "Apoplon" ;
	<http://schema.org/identifier> "drugbank:DB00206" ;
	<http://schema.org/sameAs> <http://www.drugbank.ca/drugs/DB00206> , <http://www.drugs.com/cdi/reserpine.html> .

<http://bio2rdf.org/drugbank_resource:0b62ca19764dd580eb381bfe12bdff7f> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> ".1 mg Tablet form with oral route" .

<http://bio2rdf.org/drugbank_resource:3086a4d22dbbca472f1c5ec1161f360e> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "0.82999998331069946289" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Reserpine 0.1 mg tablet" .

<http://bio2rdf.org/drugbank_resource:5df63f00794d15d27dc9dfa9969baa78> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "1.5199999809265136719" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Reserpine 0.25 mg tablet" .

<http://bio2rdf.org/drugbank_resource:7f5afbd946cf3a1ea7a02ee0e26abb52> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> ".25 mg Tablet form with oral route" .
